JP2015512951A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512951A5 JP2015512951A5 JP2015505972A JP2015505972A JP2015512951A5 JP 2015512951 A5 JP2015512951 A5 JP 2015512951A5 JP 2015505972 A JP2015505972 A JP 2015505972A JP 2015505972 A JP2015505972 A JP 2015505972A JP 2015512951 A5 JP2015512951 A5 JP 2015512951A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disorder
- dementia
- pharmaceutical composition
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical group 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 238000013019 agitation Methods 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000015046 intermittent explosive disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000000697 serotonin reuptake Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624292P | 2012-04-14 | 2012-04-14 | |
| US201261624293P | 2012-04-14 | 2012-04-14 | |
| US201261624291P | 2012-04-14 | 2012-04-14 | |
| US61/624,292 | 2012-04-14 | ||
| US61/624,291 | 2012-04-14 | ||
| US61/624,293 | 2012-04-14 | ||
| US201261671713P | 2012-07-14 | 2012-07-14 | |
| US201261671723P | 2012-07-14 | 2012-07-14 | |
| US61/671,713 | 2012-07-14 | ||
| US61/671,723 | 2012-07-14 | ||
| PCT/US2013/036514 WO2013155505A1 (en) | 2012-04-14 | 2013-04-14 | Organic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512951A JP2015512951A (ja) | 2015-04-30 |
| JP2015512951A5 true JP2015512951A5 (OSRAM) | 2016-06-09 |
| JP6242855B2 JP6242855B2 (ja) | 2017-12-06 |
Family
ID=49328233
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505973A Withdrawn JP2015514135A (ja) | 2012-04-14 | 2013-04-14 | 新規組成物および方法 |
| JP2015505971A Active JP6334511B2 (ja) | 2012-04-14 | 2013-04-14 | 新規方法 |
| JP2015505972A Active JP6242855B2 (ja) | 2012-04-14 | 2013-04-14 | 有機化合物 |
| JP2018107717A Withdrawn JP2018168161A (ja) | 2012-04-14 | 2018-06-05 | 新規組成物および方法 |
| JP2021035948A Pending JP2021098724A (ja) | 2012-04-14 | 2021-03-08 | 新規組成物および方法 |
| JP2023136052A Pending JP2023159345A (ja) | 2012-04-14 | 2023-08-24 | 新規組成物および方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505973A Withdrawn JP2015514135A (ja) | 2012-04-14 | 2013-04-14 | 新規組成物および方法 |
| JP2015505971A Active JP6334511B2 (ja) | 2012-04-14 | 2013-04-14 | 新規方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018107717A Withdrawn JP2018168161A (ja) | 2012-04-14 | 2018-06-05 | 新規組成物および方法 |
| JP2021035948A Pending JP2021098724A (ja) | 2012-04-14 | 2021-03-08 | 新規組成物および方法 |
| JP2023136052A Pending JP2023159345A (ja) | 2012-04-14 | 2023-08-24 | 新規組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US11053245B2 (OSRAM) |
| EP (4) | EP3791879A1 (OSRAM) |
| JP (6) | JP2015514135A (OSRAM) |
| KR (1) | KR20140146192A (OSRAM) |
| CN (1) | CN104519886B (OSRAM) |
| AU (1) | AU2013245702A1 (OSRAM) |
| CA (1) | CA2870303A1 (OSRAM) |
| ES (1) | ES2727815T3 (OSRAM) |
| IN (1) | IN2014DN08562A (OSRAM) |
| MX (1) | MX2014012374A (OSRAM) |
| RU (1) | RU2014145682A (OSRAM) |
| WO (3) | WO2013155504A1 (OSRAM) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102238390B1 (ko) | 2007-03-12 | 2021-04-08 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| DK2262505T3 (en) | 2008-03-12 | 2015-01-05 | Intra Cellular Therapies Inc | Substituted heterocyclic-CONCENTRATED GAMMA -carboline-SOLID |
| MX377802B (es) | 2008-05-27 | 2025-03-11 | Intra Cellular Therapies Inc | Metodos y composiciones para trastornos del sueño y otros trastornos. |
| US8993572B2 (en) | 2010-04-22 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives |
| US10039813B2 (en) | 2012-02-07 | 2018-08-07 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| RU2014145682A (ru) | 2012-04-14 | 2016-06-10 | Интра-Селлулар Терапиз, Инк | Органические соединения |
| US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| US9708322B2 (en) | 2013-03-15 | 2017-07-18 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity |
| CA3205777A1 (en) * | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia |
| US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2015154030A1 (en) * | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN104003987B (zh) * | 2014-06-03 | 2016-03-23 | 中国药科大学 | 他克林-β-咔啉异二连体类多功能胆碱酯酶抑制剂 |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| US10317418B2 (en) | 2015-02-24 | 2019-06-11 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| WO2016205631A1 (en) * | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders |
| PL3838274T3 (pl) | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| CA3016353C (en) * | 2016-03-25 | 2021-04-27 | Intra-Cellular Therapies, Inc. | Deuterated fused heterocycle gamma-carbolines and compositions thereof useful in the treatment of nervous system disorders |
| WO2017172784A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND METHOD |
| WO2017172811A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel co-crystals |
| EP3525763B1 (en) | 2016-10-12 | 2025-03-05 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
| JP6987868B2 (ja) | 2016-12-29 | 2022-01-05 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
| US11433253B2 (en) | 2017-02-15 | 2022-09-06 | The Regents Of The University Of California | Light therapy system and methods of use |
| CA3053540A1 (en) * | 2017-02-15 | 2018-08-23 | The Regents Of The University Of California | Improved light therapy system and methods of use |
| KR102398194B1 (ko) * | 2017-03-24 | 2022-05-18 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 조성물 및 방법 |
| CN110636845A (zh) * | 2017-04-10 | 2019-12-31 | 雷迪博士实验室有限公司 | 卢美哌隆对甲苯磺酸盐的无定形形式和固体分散体 |
| BR112020001666A2 (pt) * | 2017-07-26 | 2020-07-21 | Intra-Cellular Therapies, Inc. | compostos orgânicos |
| KR102667268B1 (ko) | 2017-07-26 | 2024-05-17 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| MX2020007271A (es) * | 2017-09-26 | 2020-08-17 | Intra Cellular Therapies Inc | Sales y cristales novedosos. |
| MX2020009668A (es) | 2018-03-16 | 2021-01-08 | Intra Cellular Therapies Inc | Métodos novedosos. |
| WO2019183341A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019183546A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| KR102888393B1 (ko) | 2018-06-06 | 2025-11-18 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 염 및 결정 |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| AU2019287460B2 (en) * | 2018-06-11 | 2024-02-15 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| AU2019288476A1 (en) | 2018-06-21 | 2021-03-18 | Aquestive Therapeutics, Inc. | System and method for making personalized individual unit doses containing pharmaceutical actives |
| WO2020047241A1 (en) | 2018-08-29 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| KR20210052472A (ko) | 2018-08-31 | 2021-05-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| BR112021003655A2 (pt) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | métodos novos |
| CN112955124A (zh) | 2018-09-07 | 2021-06-11 | 阿奎蒂夫疗法公司 | 具有精确的活性物溶出谱的口腔膜组合物和剂型 |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| ES3047409T3 (en) | 2018-12-17 | 2025-12-03 | Intra Cellular Therapies Inc | Substituted heterocycle fused gamma-carbolines synthesis |
| EP3898221A4 (en) | 2018-12-17 | 2022-09-14 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUND |
| IL283959B2 (en) | 2018-12-17 | 2025-01-01 | Intra Cellular Therapies Inc | Synthesis of condensed gamma-carbolines and converted heterocycles |
| US12331052B2 (en) | 2018-12-21 | 2025-06-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP7377871B2 (ja) | 2018-12-21 | 2023-11-10 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| AU2020311894B2 (en) | 2019-07-07 | 2025-06-26 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP2022549335A (ja) | 2019-09-25 | 2022-11-24 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| KR20220126286A (ko) | 2019-11-01 | 2022-09-15 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 전구약물 조성물 및 치료 방법 |
| JP2023502069A (ja) | 2019-11-14 | 2023-01-20 | アクエスティブ セラピューティクス インコーポレイテッド | マルチモーダルな組成物及び治療方法 |
| US11753419B2 (en) | 2019-12-11 | 2023-09-12 | Intra-Cellular Therapies, Inc. | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
| CA3208345A1 (en) | 2021-01-15 | 2022-07-21 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| EP4304554A1 (en) | 2021-03-09 | 2024-01-17 | Aquestive Therapeutics, Inc. | Dosage forms having equivalent biocomparable profiles |
| US20250195510A1 (en) | 2022-05-18 | 2025-06-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| EP4665344A1 (en) * | 2023-02-17 | 2025-12-24 | Intra-Cellular Therapies, Inc. | Lumateperone and derivatives thereof for modulating the nervous system |
| WO2025111568A1 (en) | 2023-11-22 | 2025-05-30 | Intra-Cellular Therapies, Inc. | Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof |
| WO2025240804A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices and methods |
| WO2025257090A1 (en) | 2024-06-10 | 2025-12-18 | Interquim, S.A. | Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
| US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
| US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
| US3606908A (en) | 1969-11-26 | 1971-09-21 | Trico Products Corp | Ventilation system for volatile fluid |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| JPS5014494A (OSRAM) * | 1973-06-11 | 1975-02-15 | ||
| US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
| IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4522944A (en) | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
| SE8304361D0 (sv) * | 1983-08-10 | 1983-08-10 | Ferrosan Ab | Novel 1-acylpiperazine derivatives novel 1-acylpiperazine derivatives |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| JPS6175A (ja) * | 1984-03-06 | 1986-01-06 | ブリストル−マイア−ズ コムパニ− | 神経弛緩剤、１‐フルオロフェニルブチル‐４‐（５‐ハロ‐２‐ピリミジニル）ピペラジン誘導体 |
| IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| ES2058068T3 (es) | 1986-03-19 | 1994-11-01 | Kumiai Chemical Industry Co | Derivados de 5h-1,3,4-tiadiazol-(3,2-a)-pirimidin-5-ona y compuestos fungicidas con contenido en dichos derivados. |
| EP0242690B1 (en) | 1986-04-07 | 1993-06-30 | Kumiai Chemical Industry Co., Ltd. | 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-one derivatives and agricultural-horticultural fungicide composition containing the same |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| ES2059602T3 (es) | 1989-04-14 | 1994-11-16 | Merz & Co Gmbh & Co | Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral. |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
| ES2236700T3 (es) | 1993-11-19 | 2005-07-16 | Janssen Pharmaceutica N.V. | 1,2-benzazoles microencapsulados. |
| US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
| US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
| US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
| US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
| US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
| US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
| GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
| US6395939B1 (en) | 1997-10-06 | 2002-05-28 | Massachusetts Institute Of Technology | Diaryl ether condensation reactions |
| ATE229499T1 (de) | 1998-02-26 | 2002-12-15 | Massachusetts Inst Technology | Metallkatalysierte arylierungen und vinylierungen von hydrazinen, hydrazonen, hydroxylaminen und oximen |
| US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
| US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
| US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| EP1097158B1 (en) | 1998-07-10 | 2006-01-25 | Massachusetts Institute Of Technology | Ligands for metals and metal-catalyzed processes |
| US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
| MXPA01006108A (es) | 1998-12-17 | 2002-09-18 | Alza Corp | Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos. |
| US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
| AR023574A1 (es) | 1999-04-23 | 2002-09-04 | Pharmacia & Upjohn Co Llc | Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| BR0012084A (pt) | 1999-06-15 | 2002-04-02 | Bristol Myers Squibb Pharma Co | Compostos, composição farmacêutica e usos dos compostos |
| US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
| CA2432185C (en) | 2000-12-20 | 2011-11-08 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| CN1266112C (zh) | 2001-04-24 | 2006-07-26 | 麻省理工学院 | 铜－催化的碳－杂原子键和碳－碳键的形成 |
| JP2005526691A (ja) | 2001-08-08 | 2005-09-08 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 治療剤１Ｈ−ピリド［４，３−ｂ］インドール |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| DK1539115T3 (da) | 2002-07-29 | 2008-01-28 | Alza Corp | Fremgangsmåder og doseringsformer til kontrolleret levering af paliperidon |
| CN1684944A (zh) | 2002-08-02 | 2005-10-19 | 麻省理工学院 | 铜催化形成碳－杂原子和碳－碳键的方法 |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| AU2003287433A1 (en) | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
| ES2364046T3 (es) | 2002-12-19 | 2011-08-23 | Bristol-Myers Squibb Company | Gamma-carbolinas tricíclicas sustituidas utilizadas como agonistas y antagonistas de los receptores de la serotonina. |
| ES2314362T3 (es) | 2003-01-16 | 2009-03-16 | Acadia Pharmaceuticals Inc. | Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas. |
| EP1654226B1 (en) | 2003-07-21 | 2008-10-22 | SmithKline Beecham Corporation | (2s,4s)-4-fluoro-1- 4-fluoro-beta-(4-fluorophenyl)-l-phenylalanyl -2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
| JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
| US20080280941A1 (en) | 2004-03-05 | 2008-11-13 | Pierre Lourtie | 8-Phenoxy-Gamma Carboline Derivatives |
| US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
| EP1793671B1 (en) * | 2004-09-20 | 2011-04-27 | Mount Sinai School of Medicine | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
| CA2581023A1 (en) * | 2004-09-21 | 2006-03-30 | Pfizer Products Inc. | N-methyl hydroxyethylamine useful in treating cns conditions |
| ES2338139T3 (es) | 2004-12-15 | 2010-05-04 | F. Hoffmann-La Roche Ag | Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador de la glicina i (glyt-1) para el tratamiento de la enfermedad de alzheimer. |
| CN101248050B (zh) * | 2005-06-06 | 2013-07-17 | 武田药品工业株式会社 | 有机化合物 |
| KR102238390B1 (ko) * | 2007-03-12 | 2021-04-08 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| JP2010535220A (ja) | 2007-08-01 | 2010-11-18 | メディベイション ニューロロジー， インコーポレイテッド | 抗精神病用の併用療法剤を使用する統合失調症の治療のための方法および組成物 |
| NZ586963A (en) | 2008-02-05 | 2012-11-30 | Clera Inc | Use of dopamine d2 receptor inhibitors for alleviating depression or improving cognition |
| DK2262505T3 (en) | 2008-03-12 | 2015-01-05 | Intra Cellular Therapies Inc | Substituted heterocyclic-CONCENTRATED GAMMA -carboline-SOLID |
| MX377802B (es) * | 2008-05-27 | 2025-03-11 | Intra Cellular Therapies Inc | Metodos y composiciones para trastornos del sueño y otros trastornos. |
| US8993572B2 (en) | 2010-04-22 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives |
| RU2014145682A (ru) | 2012-04-14 | 2016-06-10 | Интра-Селлулар Терапиз, Инк | Органические соединения |
| AU2013286823B2 (en) | 2012-07-06 | 2017-12-14 | Monash University | Immunological reagents and uses therefor |
| US9161061B2 (en) | 2013-03-15 | 2015-10-13 | Pictech Management Limited | Data storage and exchange device for color space encoded images |
| US9708322B2 (en) | 2013-03-15 | 2017-07-18 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity |
| CA3205777A1 (en) | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia |
| US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2015154030A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| PL3838274T3 (pl) | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| CA3016353C (en) | 2016-03-25 | 2021-04-27 | Intra-Cellular Therapies, Inc. | Deuterated fused heterocycle gamma-carbolines and compositions thereof useful in the treatment of nervous system disorders |
| WO2017172784A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| EP3525763B1 (en) | 2016-10-12 | 2025-03-05 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| KR102398194B1 (ko) | 2017-03-24 | 2022-05-18 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 조성물 및 방법 |
| KR102667268B1 (ko) | 2017-07-26 | 2024-05-17 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| BR112020001666A2 (pt) | 2017-07-26 | 2020-07-21 | Intra-Cellular Therapies, Inc. | compostos orgânicos |
-
2013
- 2013-04-14 RU RU2014145682A patent/RU2014145682A/ru not_active Application Discontinuation
- 2013-04-14 JP JP2015505973A patent/JP2015514135A/ja not_active Withdrawn
- 2013-04-14 AU AU2013245702A patent/AU2013245702A1/en not_active Abandoned
- 2013-04-14 MX MX2014012374A patent/MX2014012374A/es unknown
- 2013-04-14 US US14/394,469 patent/US11053245B2/en active Active
- 2013-04-14 EP EP20190036.2A patent/EP3791879A1/en active Pending
- 2013-04-14 KR KR1020147031752A patent/KR20140146192A/ko not_active Withdrawn
- 2013-04-14 EP EP13776189.6A patent/EP2836211B1/en active Active
- 2013-04-14 JP JP2015505971A patent/JP6334511B2/ja active Active
- 2013-04-14 IN IN8562DEN2014 patent/IN2014DN08562A/en unknown
- 2013-04-14 EP EP13776297.7A patent/EP2836213B1/en active Active
- 2013-04-14 JP JP2015505972A patent/JP6242855B2/ja active Active
- 2013-04-14 CN CN201380030774.2A patent/CN104519886B/zh not_active Expired - Fee Related
- 2013-04-14 ES ES13776189T patent/ES2727815T3/es active Active
- 2013-04-14 WO PCT/US2013/036512 patent/WO2013155504A1/en not_active Ceased
- 2013-04-14 US US14/394,467 patent/US9428506B2/en active Active
- 2013-04-14 WO PCT/US2013/036514 patent/WO2013155505A1/en not_active Ceased
- 2013-04-14 WO PCT/US2013/036515 patent/WO2013155506A1/en not_active Ceased
- 2013-04-14 EP EP13776208.4A patent/EP2836212A4/en not_active Ceased
- 2013-04-14 CA CA2870303A patent/CA2870303A1/en not_active Abandoned
- 2013-04-14 US US14/394,470 patent/US20150080404A1/en not_active Abandoned
-
2018
- 2018-06-05 JP JP2018107717A patent/JP2018168161A/ja not_active Withdrawn
-
2019
- 2019-09-27 US US16/585,251 patent/US11124514B2/en active Active
-
2020
- 2020-07-10 US US16/926,551 patent/US20200407362A1/en active Pending
- 2020-07-10 US US16/926,552 patent/US20210002280A1/en active Pending
-
2021
- 2021-03-08 JP JP2021035948A patent/JP2021098724A/ja active Pending
- 2021-08-18 US US17/405,736 patent/US11958852B2/en active Active
-
2023
- 2023-08-24 JP JP2023136052A patent/JP2023159345A/ja active Pending
-
2024
- 2024-03-11 US US18/601,923 patent/US20240208974A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512951A5 (OSRAM) | ||
| RU2014145682A (ru) | Органические соединения | |
| JP2015511958A5 (OSRAM) | ||
| RU2018130727A (ru) | Органические соединения | |
| JP2018519329A5 (OSRAM) | ||
| JP2018519351A5 (OSRAM) | ||
| JP2012521994A5 (OSRAM) | ||
| MX386258B (es) | Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas | |
| RU2018104278A (ru) | Оксистеролы и способы их применения | |
| JP2018519328A5 (OSRAM) | ||
| JP2020502092A5 (OSRAM) | ||
| JP2017531020A5 (OSRAM) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2014526469A5 (OSRAM) | ||
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| MY167396A (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | |
| JP2015537020A5 (OSRAM) | ||
| JP2013032389A5 (OSRAM) | ||
| JP2017514910A5 (OSRAM) | ||
| JP2017533968A5 (OSRAM) | ||
| HRP20211282T1 (hr) | Oksisteroli i postupci njihovog korištenja | |
| JP2015508092A5 (OSRAM) | ||
| JP2015523406A5 (OSRAM) | ||
| JP2012515150A5 (OSRAM) | ||
| JP2016537338A5 (OSRAM) |